Objective: Despite the availability of a highly effective and safe vaccine against hepatitis B
virus (HBV) infection for 40 years, still almost 300 million persons are estimated to be …

Annually, more than 1.5 million preventable new hepatitis B (HBV) infections continue to
occur, with an estimated global burden of 296 million individuals living with chronic hepatitis …

Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to
chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a …

Abstract Hepatitis B (HB) virus (HBV) infection, which causes liver cirrhosis and
hepatocellular carcinoma, is endemic worldwide. Hepatitis B vaccines became commercially …

Hepatitis B virus infection is a global health problem. Worldwide, about 360 million people
are chronically infected with the virus. They continue to spread the virus to others and are …

The Viral Hepatitis Prevention Board (VHPB) organized an international meeting in Milan in
November 2011 on the question of whether completing a course of hepatitis B vaccination …

Hepatitis B virus (HBV) infection is a world wide public health problem of major concern.
HBV infection may lead to chronic liver disease, including cirrhosis and hepatocellular …

Guidelines for the prevention of hepatitis B with vaccine are issued by a number of
organizations. In the United States, the use of hepatitis B vaccine is addressed in …

Hepatitis B virus (HBV) infection is a global public health problem that is closely related to
liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic …

One of the major successes in the area of vaccinology is the emergence, development and
usage of hepatitis B vaccine (a prophylactic vaccine against HBV). Hepatitis B vaccine has …